Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220011319COMPOSITIONS AND METHODS OF PROGNOSIS AND CLASSIFICATION FOR PREECLAMPSIA
US 13.01.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No 17291858 Applicant The Board of Trustees of the Leland Stanford Junior University Inventor Brice L. Gauilliere

Multiparametric analysis is performed at the single cell level of biological samples obtained from an individual during pregnancy to obtain a determination of changes in immune cell subsets, which changes include, without limitation, altered activation states of proteins involved in signaling pathways. Changes occur in signaling pathways of these immune cells that are predictive of propensity to develop preeclampsia in the pregnancy.

2.WO/2022/007251NANO-PLASMON RESONANCE-BASED QUANTITATIVE DETECTION METHOD FOR NOVEL CORONAVIRUS PARTICLES
WO 13.01.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/CN2020/123839 Applicant LIANGZHUN (SHANGHAI) MEDICAL EQUIPMENT CO., LTD. Inventor HUANG, Li Ping
A nano-plasmon resonance-based quantitative detection method for novel coronavirus particles, comprising: preparing a plasmon resonance coupling effect device (S1) and preparing gold nanoparticles used for amplifying detection signals (S2); modifying a SARS‑COV‑2 capture antibody on the surface of a nano-plasmon resonance sensor chip (S3), and labeling the gold nanoparticles by using a SARS‑COV‑2 labeled antibody (S4); adding SARS‑CoV‑2 virus particle samples of different titers to the labeled gold nanoparticles (S5); adding a mixed solution to an orifice plate to be tested to complete the capture of a SARS-CoV-2 virus particle and labeled nano-gold particle complex (S6); and by means of detecting the change curve of the differences over time in absorbance at a specific wavelength before and after sample addition, quantitatively detecting SARS-CoV-2 virus particles (S7).
3.WO/2022/008931IMPROVEMENTS IN OR RELATING TO AN APPARATUS FOR IMAGING
WO 13.01.2022
Int.Class G01N 21/51
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
17Systems in which incident light is modified in accordance with the properties of the material investigated
47Scattering, i.e. diffuse reflection
49within a body or fluid
51inside a container, e.g. in an ampoule
Appl.No PCT/GB2021/051768 Applicant VIDYA HOLDINGS LTD Inventor DORRESTIJN, Marko
An apparatus for imaging a plurality of assay spots is provided. The apparatus comprising a plurality of assay spots deposited onto a substrate, each assay spot comprising one or more capture components and/or one or more detection reagents; and a total internal reflection excitation microscope comprising a light source for illuminating the assay spots; a lens system is configured to launch light towards the substrate and to collect the emitted, reflected or scattered light from the assay spots, wherein the lens system comprises an objective lens; and a detector configured to detect the collected emitted, reflected or scattered light from the lens system, wherein the detector is further configured to image multiple assay spots simultaneously within a field of view.
4.WO/2022/008976USE OF GDF11 TO DIAGNOSE AND TREAT ANXIETY AND DEPRESSION
WO 13.01.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/IB2021/000495 Applicant INSTITUT PASTEUR Inventor KATSIMPARDI, Lida
Provided are methods for the detection of GDF11 in a subject having or suspected of having a mood and/or anxiety disorder, comprising providing a sample from a subject having or suspected of having a mood and/or anxiety disorder; contacting the sample with a GDF11-binding molecule; and detecting bound GDF11. Also provided are methods of diagnosing or characterizing a mood and/or anxiety disorder in a subject, comprising providing a sample from a subject; contacting the sample with a GDF11-binding molecule; detecting bound GDF11; and comparing the levels of detected bound GDF11 to healthy reference levels. Also provided are methods of treating or preventing a mood and/or anxiety disorder and/or accelerated aging in a subject in need thereof, comprising administering to the subject an agent or composition which increases the levels of GDF11 polypeptide in the subject.
5.WO/2022/010806METHODS FOR REDUCING THE INTERFERENCE OF DRUGS THAT BIND THERAPEUTIC TARGETS EXPRESSED ON BLOOD CELLS IN SEROLOGICAL ASSAYS
WO 13.01.2022
Int.Class G01N 33/80
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
80involving blood groups or blood types
Appl.No PCT/US2021/040374 Applicant ALX ONCOLOGY INC. Inventor SIM, Bang Janet
Provided are methods of reducing and/or preventing interference by a drug comprising (i) an antibody Fc region and (ii) a moiety that binds a therapeutic target that is expressed on the surface of blood cells (e.g., red blood cells and/or platelets).
6.WO/2022/011001METHOD FOR ANTIGEN DETECTION FROM DIRECT CLINICAL SAMPLES
WO 13.01.2022
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
Appl.No PCT/US2021/040672 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor RODWELL, Timothy
In one aspect, the disclosure relates to test strips for detecting and/or monitoring the treatment of a disease in a subject. The test strips are inexpensive and disposable and can be used directly with clinical biological samples from patients including, but not limited to, blood, plasma, saliva, and urine. Also disclosed are methods of using the test strips to quantify antigens produced by a virus or microorganism causing an infectious disease. The methods can be conducted at a point of care for a patient and do not require expensive equipment or extensive operator training. The methods are also rapid to complete and can be used to monitor progress in the treatment of a disease This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
7.20220011219DISEASE DIAGNOSIS USING SPECTROSCOPY AND MACHINE LEARNING
US 13.01.2022
Int.Class G01N 21/35
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
17Systems in which incident light is modified in accordance with the properties of the material investigated
25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
31Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
35using infra-red light
Appl.No 17368803 Applicant Massachusetts Institute of Technology Inventor Dimitris Bertsimas

Aspects of the present application relate to techniques of diagnosing whether a pathogen (e.g., SARS-CoV-2) is present in a subject using infrared (IR) spectroscopy and machine learning techniques. The techniques use spectral data obtained from performing IR spectroscopy on a biological sample (e.g., saliva or nasal sample, or genetic material extracted therefrom) to generate a set of feature values. The feature values are provided as input to a machine learning model to obtain output indicating whether the pathogen is present in the biological sample. The output of the machine learning model may be used to determine a diagnosis result for a subject.

8.WO/2022/009577BLOOD MEASUREMENT DEVICE
WO 13.01.2022
Int.Class G01N 33/483
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
Appl.No PCT/JP2021/021421 Applicant LOOK TEC CO.,LTD. Inventor OGURA Hitoshi
A blood measurement device (10) comprises: a light emitting unit (11) for emitting a light ray that passes through a site (18) being measured; a light receiving unit (19) for receiving the light ray that has passed through the site (18) being measured; an integrating sphere unit (14) disposed in a light path along which the light ray emitted from the light emitting unit (11) travels to the light receiving unit (19), the integrating sphere unit (14) having a reflective surface (26) formed therein for reflecting the light ray; a light inlet (23) that is an opening provided in the integrating sphere unit (14) and through which the light ray emitted from the light emitting unit (11) enters the inside of the integrating sphere unit (14); and a light outlet (16) that is an opening provided in the integrating sphere unit (14) and through which the light ray reflected by the reflective surface (26) of the integrating sphere unit (14) is emitted from the integrating sphere unit (14) toward the site being measured (18).
9.WO/2022/010312COMPOSITION COMPRISING MUC4 GENE MUTATION DETECTING AGENT FOR PREDICTION OR DIAGNOSIS OF GASTRIC CANCER
WO 13.01.2022
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No PCT/KR2021/008803 Applicant SEOUL NATIONAL UNIVERSITY HOSPITAL Inventor KIM, Nayoung
The present invention in which a MUC4 gene is discovered as a biomarker for predicting or diagnosis gastric cancer relates to a composition and kit capable of predicting or diagnosing gastric cancer when a mutation is present on the gene and to a method for providing information therefor. The composition according to an aspect of the present invention allows the detection of a mutation at one or more loci selected from the group consisting of rs774527434, rs534579185, rs77250903, rs868067409, rs531395109, rs754808151, rs1304612772, rs774907241, rs771925912, rs745342765, rs148735556, rs11717039, and rs547775645 on MUC4 gene, thus exhibiting an excellent effect of predicting or diagnosing gastric cancer in a cost and time effective manner for multiple subjects to be tested.
10.WO/2022/011197COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER
WO 13.01.2022
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/US2021/040971 Applicant MERCY BIOANALYTICS, INC. Inventor SEDLAK, Joseph Charles
The present disclosure in one aspect provides technologies for detection of lung cancer, e.g, early detection of lung cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to lung cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g, by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.